PIK3CB and breast carcinoma: In breast cancer, gedatolisib (PF-05212384) is a dual PI3K/mTOR inhibitor that was evaluated in combination with either docetaxel, cisplatin, or dacomitinib in triple-negative breast cancer (NCT01920061).